Pembrolizumab is a humanized IgG4 monoclonal antibody that inhibits the interaction between the PD-1 protein (programmed death protein 1) present on T cells of the immune system with its ligand (PD-L1) present on tumor cells resulting in the activation of the immune system to attack tumor cells [9]. Here, CD274 is linked to neoplasm.